Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells

Jia, Dongxuan; Entersz, Ildiko; Butler, Christine; Foty, Ramsey A.

doi:10.1186/1471-2407-12-94

Cited by 34 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protein has been found to be expressed in BC [40, 41], and other cancers [37, 42, 43]. Moreover, it has been reported that FN could induce progression of various cancer cells [36, 37] and is strongly expressed in breast carcinoma, and its distribution is different from that of normal breast parenchyma [38, 39].…”

Section: Discussionmentioning

confidence: 99%

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

et al. 2016

View full text Add to dashboard Cite

Extracellular vesicles (EVs) secreted from cancer cells have potential for generating cancer biomarker signatures. Fibronectin (FN) was selected as a biomarker candidate, due to the presence in surface on EVs secreted from human breast cancer cell lines. A subsequent study used two types of enzyme-linked immunosorbent assays (ELISA) to determine the presence of these proteins in plasma samples from disease-free individuals (n=70), patients with BC (n=240), BC patients after surgical resection (n=40), patients with benign breast tumor (n=55), and patients with non-cancerous diseases (thyroiditis, gastritis, hepatitis B, and rheumatoid arthritis; n=80). FN levels were significantly elevated (p<. 0001) at all stages of BC, and returned to normal after tumor removal. The diagnostic accuracy for FN detection in extracellular vesicles (ELISA method 1) (area under the curve, 0.81; 95% CI, 0.76 to 0.86; sensitivity of 65.1% and specificity of 83.2%) were also better than those for FN detection in the plasma (ELISA method 2) (area under the curve, 0.77; 95% CI, 0.72 to 0.83; sensitivity of 69.2% and specificity of 73.3%) in BC. The diagnostic accuracy of plasma FN was similar in both the early-stage BC and all BC patients, as well as in the two sets. This liquid biopsy to detect FN on circulating EVs could be a promising method to detect early breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The ability of prostate cancer cells to assemble a fibronectin matrix is correlated with the ability to form cohesive aggregates and cellular α 5 β 1 expression. High α 5 β 1 levels and fibronectin matrix assembly are inversely correlated with invasiveness; loss of α 5 β 1 allows cell detachment, leading to intravasation and metastasis [116]. Agonism of α 5 β 1 has therefore been proposed as an anti-metastatic strategy and the MEK inhibitor AZD6244 has been shown to promote cell adhesion, possibly by activating α 5 β 1 [116], however such an approach will require careful assessment for safety, since α 5 β 1 -mediated adhesion and angiogenesis could promote the establishment of metastases once cells have detached from the main tumour.…”

Section: Consequences Of Integrin Expression In Prostate Cancermentioning

confidence: 99%

“…High α 5 β 1 levels and fibronectin matrix assembly are inversely correlated with invasiveness; loss of α 5 β 1 allows cell detachment, leading to intravasation and metastasis [116]. Agonism of α 5 β 1 has therefore been proposed as an anti-metastatic strategy and the MEK inhibitor AZD6244 has been shown to promote cell adhesion, possibly by activating α 5 β 1 [116], however such an approach will require careful assessment for safety, since α 5 β 1 -mediated adhesion and angiogenesis could promote the establishment of metastases once cells have detached from the main tumour. Recent work has shown that the actin regulatory protein Mena is required for α 5 β 1 -mediated functions and signalling in fibroblasts [117].…”

Section: Consequences Of Integrin Expression In Prostate Cancermentioning

confidence: 99%

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis

Sutherland

Gordon

Shnyder

et al. 2012

Cancers

View full text Add to dashboard Cite

Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cross-talk between the cell and extracellular matrix, enhancing the growth, migration, invasion and metastasis of cancer cells. Progression and metastasis of prostate adenocarcinoma is strongly associated with changes in integrin expression, notably abnormal expression and activation of the β3 integrins in tumour cells, which promotes haematogenous spread and tumour growth in bone. As such, influencing integrin cell expression and function using targeted therapeutics represents a potential treatment for bone metastasis, the most common and debilitating complication of advanced prostate cancer. In this review, we highlight the multiple ways in which RGD-binding integrins contribute to prostate cancer progression and metastasis, and identify the rationale for development of multi-integrin antagonists targeting the RGD-binding subfamily as molecularly targeted agents for its treatment.

show abstract

“…showed that only wild-type, fully functional α5β1 integrin could promote FNMA by CHO cells and that only a fully developed fibronectin matrix could give rise to increased intercellular cohesion [48]. The concepts and methods underlying integrin–ECM-based cohesion have now been applied to studies of malignant invasion in various cancer models, including prostate cancer [49] and, more pertinent to this article, GBM [50]. In both models, ECM-based cohesion appears to be correlated with FNMA and could be pharmacologically induced by treatment with dexamethasone.…”

Section: Integrins As Mediators Of Cell-cell Cohesionmentioning

confidence: 99%

Tumor Cohesion and Glioblastoma Cell Dispersal

Foty¹

2013

Future Oncol.

Self Cite

View full text Add to dashboard Cite

Patients with glioblastoma typically present when tumors are at an advanced stage. Surgical resection, radiotherapy and adjuvant chemotherapy are currently the standard of care for glioblastoma. However, due to the infiltrative and dispersive nature of the tumor, recurrence rate remains high and typically results in very poor prognosis. Efforts to treat the primary tumor are, therefore, palliative rather than curative. From a practical perspective, controlling growth and dispersal of the recurrence may have a greater impact on disease-free survival, In order for cells to disperse, they must first detach from the mass. Preventing detachment may keep tumors that recur more localized and perhaps more amenable to therapy. Here we introduce a new perspective in which a quantifiable mechanical property, namely tissue surface tension, can provide novel information on tumor behavior. The overall theme of the discussion will attempt to integrate how adhesion molecules can alter a tumor’s mechanical properties and how, in turn, these properties can be modified to prevent tumor cell detachment and dispersal.

show abstract

Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells

Cited by 34 publications

References 32 publications

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis

Tumor Cohesion and Glioblastoma Cell Dispersal

Contact Info

Product

Resources

About